Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database

Haematologica. 2024 Jul 1;109(7):2277-2283. doi: 10.3324/haematol.2023.283846.
No abstract available

Publication types

  • Letter
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine* / adverse effects
  • Adenine* / analogs & derivatives
  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Databases, Factual
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Male
  • Middle Aged
  • Piperidines* / adverse effects
  • Piperidines* / therapeutic use
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles* / adverse effects
  • Pyrazoles* / therapeutic use
  • Pyrimidines* / adverse effects
  • Pyrimidines* / therapeutic use

Substances

  • ibrutinib
  • Piperidines
  • Adenine
  • Pyrazoles
  • Pyrimidines
  • zanubrutinib
  • Protein Kinase Inhibitors
  • Antineoplastic Agents

Grants and funding

Funding: This work was supported by funding from BeiGene USA, Inc. Data analyses were performed by biostatisticians at BeiGene USA, Inc, and BeiGene (Beijing) China.